Avid prepares to present findings of Alzheimer's study

06/23/2010 | New York Times (tiered subscription model), The

Avid Radiopharmaceuticals, a company that developed fluoride 18-based dyes for use in PET scans of amyloid plaques, said it has received the results of a study using its dye to determine whether Alzheimer's disease diagnosed through a PET scan correlates with that determined through a brain autopsy. The results, to be presented at the Alzheimer's Association meeting next month, will "have a big impact on Alzheimer's disease," said Dr. Daniel Skovronsky, founder of the company.

View Full Article in:

New York Times (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
ISHN - Chief Compliance Officer
Mountain States Health Alliance
Johnson City, TN
Actuary
Meridian Health Plan
Detroit, MI
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Director, Payer Marketing
Avalere Health
Washington, DC